Genetic Medicines For Kidney Diseases: Jason Coloma on The Long Run

Jason Coloma is today’s guest on The Long Run.

Jason is the CEO of South San Francisco-based Maze Therapeutics. The company is developing small molecule drugs to halt or potentially reverse kidney diseases. The drug discovery work at Maze is grounded in human genetics, looking at large pools of data to see how variants of one kind or another can make people sick, or protect them from falling ill.

Jason Coloma, CEO, Maze Therapeutics

Maze went public in early 2025, after surviving several lean years of biotech financing. An important partnership unraveled after the federal government sought to block it on antitrust grounds. Maze found a way to bounce back, and enticed a new partner to support that program. Those battles have strengthened the company culture. Maze is now in position to find out in the next year or so whether its two lead programs – an APOL1 directed kidney drug and another aimed at SLC6a19 – are good enough to pass Phase II clinical trial scrutiny.

Like many biotech industry leaders, Jason didn’t take a linear path into this moment of possibility in medicine. That’s part of what makes his story, and Maze’s story, so interesting.

The Long Run is sponsored by

So far 2026 has been a year of transition for healthcare and life sciences. Over the first half of this year, the AlphaSense healthcare research team analyzed the individual stories moving the needle across the life sciences ecosystem as part of the Sector Spotlight series. Download the eight spotlights here. They featuring the high-stakes battles for new drug markets (like oral GLP-1s and targeted radioligand therapies), a resurgent biotech IPO market, and more.

Follow the sector’s key debates during 2H26 and beyond, with the latest Sector Spotlights directly in AlphaSense.

Quick question: when was the last time a CRO told you what something costs before you signed an NDA, sat through two scoping calls, and waited a week for a Scope of Work? In bioanalysis, pricing gets treated like a closely-guarded secret. Dash Bio thinks that’s backward. It publishes pricing publicly, on its website, and even has a calculator that shows how the price changes if you redesign your study. You can see what your study costs before you talk to a human being. No surprise line items, no “it depends”, no games. Dash was built to be the bioanalysis company that’s actually straightforward to work with: transparent pricing, guaranteed timelines, and data in days, not months.

If you’re tired of pricing that feels like a negotiation every single time, run your bioanalysis with Dash.

Visit dash.bio/pricing and see exactly how much your next bioanalysis study will cost.

Now please enjoy this episode of The Long Run with Jason Coloma.